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Integrins mediate the lymphocyte migration into an infected tissue, and these cells 
are essential for controlling the multiplication of many intracellular parasites such as 
Trypanosoma cruzi, the causative agent of Chagas disease. Here, we explore LFA-1 
and VLA-4 roles in the migration of specific CD8+ T cells generated by heterologous 
prime-boost immunization during experimental infection with T. cruzi. To this end, 
vaccinated mice were treated with monoclonal anti-LFA-1 and/or anti-VLA-4 to block 
these molecules. After anti-LFA-1, but not anti-VLA-4 treatment, all vaccinated mice 
displayed increased blood and tissue parasitemia, and quickly succumbed to infection. 
In addition, there was an accumulation of specific CD8+ T cells in the spleen and lymph 
nodes and a decrease in the number of those cells, especially in the heart, suggesting 
that LFA-1 is important for the output of specific CD8+ T cells from secondary lymphoid 
organs into infected organs such as the heart. The treatment did not alter CD8+ T cell 
effector functions such as the production of pro-inflammatory cytokines and granzyme 
B, and maintained the proliferative capacity after treatment. However, the specific CD8+ 
T cell direct cytotoxicity was impaired after LFA-1 blockade. Also, these cells expressed 
higher levels of Fas/CD95 on the surface, suggesting that they are susceptible to 
programmed cell death by the extrinsic pathway. We conclude that LFA-1 plays an 
important role in the migration of specific CD8+ T cells and in the direct cytotoxicity of 
these cells.
Keywords: vaccination, Trypanosoma cruzi, migration, integrins, specific cD8+ T cells
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inTrODUcTiOn
Chagas disease, caused by the intracellular parasite Trypanosoma 
cruzi, is a major public health problem, with about seven mil-
lion people infected worldwide (1). CD8+ T cells are crucial for 
controlling the multiplication of intracellular pathogens such as 
T. cruzi. These cells control the infection by secreting cytokines 
such as IFN-γ and TNF-α, or by direct cytotoxicity against 
infected target cells (2). The heterologous prime-boost vaccina-
tion strategy has shown significant results in the induction of 
specific CD8+ T cells and the generation of an optimal protective 
immune response. Among several possible combinations of 
vectors for this type of immunization, we used a plasmid vector 
for priming and an adenovirus-Ad5 vector (replication-defective 
human Ad type 5) for boosting, both containing an insertion of 
the ASP-2 gene (T. cruzi’s amastigote surface protein 2 gene). 
This type of immunization was capable of protecting A/Sn mice 
that are highly susceptible to experimental infection with T. cruzi 
(3, 4).
The results obtained in preclinical experimental models with 
heterologous prime-boost immunization have boosted recent 
clinical trials (5–10). In 2013, the first results of a Phase II clinical 
trial were published. In that study, a number of volunteers, who 
were vaccinated with plasmid DNA followed by immunization 
with Ad5, both encoding the genes of the apical membrane 
antigen 1 and the immunodominant surface protein of the 
Plasmodium falciparum circumsporozoite protein, developed 
immunity to malaria (11).
To the CD8+ T cells exert their effector function, these cells 
must migrate to non-lymphoid peripheral tissues where the 
infection occurs. Our group recently demonstrated that the 
protection generated by heterologous prime-boost immuniza-
tion regimen depends on the recirculation of specific CD8+ 
T  cells, since immunized and protected A/Sn mice became 
susceptible to the experimental challenge with T. cruzi after 
FTY720 drug treatment (12). This immunosuppressive drug 
reduces lymphocyte recirculation by altering T  cell signaling 
via sphingosine-1-phosphate receptor-1 (S1Pr1). This leads in 
sustained inhibition of S1Pr1 signaling, trapping T cells within 
the secondary lymphoid with no impairment of T cell activation 
(12, 13). Based on this knowledge, we hypothesized that other 
molecules, such as integrins, could be involved in the CD8+ T cell 
migration. The integrins are heterodimers that composed of an 
alpha and beta chain; LFA-1 is composed of αLβ2 (CD11a/CD18) 
chains, and VLA-4, of α4β1 (CD49d/CD29) chains. These mol-
ecules play an important role in the formation of immunological 
synapses and signal transduction, which result, for example, in 
cell migration, activation, and/or proliferation (14, 15). During 
transendothelial migration, chemokine-triggered activation of 
both LFA-1 and VLA-4 leads them to change their conformations 
and strongly bind to intercellular adhesion molecules (ICAMs 
and VCAMs, respectively) on endothelial cells and, thus, migrate 
into the tissues (16). In β2 integrin-deficient mice, LFA-1 shows 
a significant reduction in the in  vitro lymphocyte migration, 
strengthening the role of this molecule in leukocyte migration 
(17). The LFA-1 role in lymphocyte migration has also been dem-
onstrated in the experimental autoimmune encephalomyelitis, 
in which regulatory CD4+ T  cells can migrate to the CNS via 
LFA-1 (18). Its role has also been demonstrated in allografts, 
and the antagonism of this molecule is a very effective inhibitor 
of acute rejection, thus prolonging allograft survival in rodents 
(19). VLA-4 has also been studied in liver allograft rejections, 
where it seems responsible for the migration of effector CD8+ 
T cells and transplant rejection along with LFA-1 (20, 21). During 
infection by intracellular parasites such as T. cruzi, specifically 
by the Colombian strain, there is a predominance of effector 
CD8+ T lymphocytes (CTLs) with high expression of LFA-1 and 
VLA-4 in the myocardium of infected mice (22). In addition, 
the high expression of LFA-1 on the surface of Pfn+CD8+ T cells 
during the acute and chronic phases has been demonstrated (23). 
However, the dominance of these cells in cardiac tissue favors 
the progression of the inflammatory reaction, culminating in 
Chronic Chagas heart disease (24).
Herein, we tested whether LFA-1 and VLA-4 integrins 
were key mediators for T  cell-mediated protective immunity 
against T. cruzi infection. For that purpose, mice were vac-
cinated with heterologous prime-boost vaccine (recombinant 
plasmid DNA/AdHu5), challenged and treated with blocking 
antibodies to LFA-1 and/or VLA-4. Our results demonstrate 
that LFA-1, but not VLA-4, is essential for protective immune 
response of highly susceptible mice against T. cruzi infection. 
Also, the study demonstrated that LFA-1 mediates CD8+ T cells 
migration into infected tissues, such as the heart, and plays 
an important role in CD8+ T  cells cytotoxicity for parasite 
clearance.
MaTerials anD MeThODs
ethics statement
This study was carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory mice 
of the Brazilian National Council of Animal Experimentation 
(http://www.mctic.gov.br/mctic/opencms/textogeral/concea.
html). The protocol was approved by the Ethical Committee for 
Animal Experimentation at the Federal University of Sao Paulo 
(Id # CEP 7559051115).
Mice and Parasites
Female 5- to 8-week-old A/Sn or C57BL/6 mice were purchased 
from the Federal University of São Paulo. ICAM-1-deficient mice 
were kindly supplied by Dr. João Santana, Ribeirão Preto School 
of Medicine-FMPR. Parasites of the Y strain of T. cruzi were 
used in this study (2, 3). Blood trypomastigotes of the Y strain 
of T. cruzi were maintained by weekly passages in A/Sn mice at 
the Xenodiagnosis Laboratory of Dante Pazzenese Cardiology 
Institute. Bloodstream trypomastigotes were obtained from mice 
infected 7–28 days earlier with parasites of the Y strain. For in vivo 
experiments, each mouse was inoculated with 150 trypomastig-
otes (A/Sn) or 104 trypomastigotes (C57BL/6) diluted in 0.2 mL 
phosphate-buffered saline (PBS) and administrated subcutane-
ously (s.c.) in the base of the tail. Parasitemia was determined by 
collecting 5 μL of blood, and parasites were counted on the light 
microscope (25).
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immunization Protocol
In this study, we used the heterologous prime-boost immu-
nization protocol with plasmid pIgSPCl.9 and the human 
replication-defective adenovirus type 5 containing the ASP-2 
gene, as described previously (3, 26). Briefly, this immunization 
consists of a dose of plasmid DNA as a prime (pcDNA3 control or 
pIgSPClone9). The mice were intramuscularly inoculated (i.m.) 
with 50 µg of plasmid DNA into each tibialis anterioris muscle. 
Three weeks after the first immunization, mice were boosted with 
2 × 108 plaque-forming units of the adenoviral vectors Adβ-gal 
or AdASP-2. Both injections were performed via intramuscular 
route (tibialis anterior muscle).
Peptide
TEWETGQI peptide was synthesized by GenScript and obtained 
at purity higher than 95%. The TEWETGQI epitope expressed 
on ASP-2 surface is target of CD8+ T cells and was identified 
previously (27). It was used for specific CD8+ T cell stimula-
tion in  vitro and ex vivo. The H2KK-TEWETGQI multimer, 
labeled with fluorophore APC, was purchased from Immudex 
(Copenhagen, Denmark) and used for specific CD8+ T  cell 
detection in tissues.
Treatment with Monoclonal antibodies
Anti-LFA-1 (anti-CD11a, clone M17-4) and anti-VLA-4 (anti-
CD49d, clone PS/2) monoclonal antibodies were purchased 
from BioXcell; in addition, we used Rat IgG2a (clone 2A3) 
isotype control. The in vivo treatment was performed with 10 i.p. 
injections of 250 µg of mAb/mouse (every 48 h after infection, 
until day 20 after infection). The concentration of LFA-1 used 
for in vivo treatment was the same used by Reisman et al. (28). 
To evaluate the efficiency of LFA-1 integrin blockade, C57BL/6 
mice were infected with 104 trypomastigote forms of Y strain, 
and 12 days post infection, the splenocytes were harvested and 
incubated in  vitro for 24  h at 30°C with monoclonal 250  µg/
mL of 2A3 isotype control or anti-LFA-1 in complete medium 
[1% NEAA, 1% l-glutamine, 1% vitamins and 1% pyruvate, 
0.1% 2-ME, 10% fetal bovine serum (FBS) (HyClone)]. After 
incubation, splenocytes were washed and labeled with anti-
CD8 PerCP (clone 53-6.7, BD) and anti-CD11a FITC (clone 
2D7, BD), fixed with 1% paraformaldehyde and analyzed by 
flow cytometry. Concomitantly, we also evaluated the blockade 
of the LFA-1 molecule stimulating splenocytes in  vitro with 
1  µg/mL anti-CD3 (clone 145-2C11, eBioscience) in complete 
medium for 72  h at 37°C and 5% CO2. On the second day 
of incubation, 250  µg of 2A3 isotype control or anti-LFA-1 
monoclonal antibodies were added to the culture. On the third 
day of culture, cells were harvested and labeled with anti-CD8 
PerCP and anti-CD11a FITC for flow cytometric analysis. LFA-1 
expression was performed on gated CD8+ T cells, according to 
Figures S1A,B in Supplementary Material, treatment with mono-
clonal anti-LFA-1 blocked most LFA-1 molecule expressed on 
activated CD8+ T cells and after anti-LFA-1 FITC staining there 
was a lower CD11a MFI on the surface of these cells, indicating 
that there is competition between anti-LFA-1 monoclonal anti-
bodies used for in vivo blocking (clone M17-4) and anti-CD11a 
FITC (clone 2D7, BD) used for flow cytometry labeling.
real-time Pcr
Hearts, livers, and spleens from the T. cruzi-infected, immu-
nized, and/or treated mice with anti-LFA-1 A/Sn were used for 
extracting DNA. The extraction protocol, the specific primers 
for a satellite DNA region of the parasite, and the RT-PCR reac-
tion using the TaqMan Universal Master Mix II with UNG were 
adapted from Piron and colleagues (29). For the race plates, we 
used StepOnePlus (Applied Biosystems®), and distilled water for 
negative control reaction.
enzyme-linked immunospot (elisPOT) 
assay
Sterile PBS containing 10  µg/mL of anti-mouse IFN-γ mono-
clonal antibody (clone R4-6A2, Pharmingen) was added onto 
nitrocellulose 96-well flat-bottom plates; after 24  h, the plates 
were washed with RPMI and blocked with RPMI containing 10% 
FBS for 2 h. Following, 1 × 106 responder cells from spleen, liver, 
or lymph node were incubated with 3 × 105 antigen-presenting 
cells in complete medium [1% NEAA, 1% l-glutamine, 1% 
vitamins and 1% pyruvate, 0.1% 2-ME, 10% FBS (HyClone), 
and 20  U/mL mouse recombinant IL-2 (SIGMA)]. The plate 
was incubated in the presence or absence of 10 µM of peptide 
TEWETGQI. After 24 h, the plates were washed three times with 
PBS, and five times with PBS–Tween 20 (0.05% Tween). Each 
well received biotinylated anti-mouse monoclonal antibody 
(clone XMG1.2, Pharmingen) diluted in PBS-0.05% Tween 20 
at a final concentration of 2 µg/mL. The plates were incubated 
with streptavidin-peroxidase (BD) and developed by adding 
peroxidase substrate (50  mM Tris–HCl, pH 7.5, containing 
1 mg/mL DAB and 1 µL/mL 30% hydrogen peroxide, both from 
SIGMA). The number of IFN-γ-producing cells was determined 
using a stereoscope.
intracellular cytokine staining
Two million cells from the spleen, lymph node, or liver were 
treated with ACK buffer (NH4Cl, 0.15  M; KHCO3, 10  mM; 
Na2-EDTA 0.1 mM; pH = 7.4). ICS was performed after in vitro 
culture of splenocytes in presence or absence of 10 µM of peptide 
TEWETGQI as described previously (25). Cells were washed 
three times in plain RPMI and resuspended in cell culture 
medium consisting of RPMI 1640 medium supplemented with 
10 mM HEPES, 0.2% sodium bicarbonate, 59 mg/L of penicillin, 
133 mg/L of streptomycin, 10% HyClone FBS, 2 mM l-glutamine, 
1 mM sodium pyruvate, 55 µM 2-mercaptoethanol. The viability 
of the cells was evaluated using 0.2% trypan blue exclusion dye to 
discriminate between live and dead cells. Cell concentration was 
adjusted to 2 × 106 cells/mL in cell culture medium containing 
CD107a FITC antibody (clone 1D4B, BD), anti-CD28 (clone 
37.51, BD), BD Golgi-Plug (1 µL/mL), and monensin (5 µg/mL) 
and incubated no longer than 12 h in V-bottom 96-well plates 
(Corning) in a final volume of 200 µL in duplicate, at 37°C in a 
humid environment containing 5% CO2. After 12 h incubation, 
cells were stained for surface markers with anti-CD8 PERCP 
antibody (clone 53-6.7, BD) on ice for 30 min. To detect IFN-
γ, TNF or granzyme B by intracellular staining, cells were then 
washed twice in buffer containing PBS, 0.5% bovine serum 
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albumin (BSA), and 2  mM EDTA, fixed and permeabilized 
with BD perm/wash buffer. After being washed twice with BD 
perm/wash buffer, cells were stained for intracellular markers 
using APC-labeled anti-IFN-γ (clone XMG1.2, BD), PE-labeled 
anti-TNF-α (clone MP6-XT22, BD), and anti-granzyme B PE 
(clone GB11, INVITROGEN) for 20  min on ice. Finally, cells 
were washed twice with BD perm/wash buffer and fixed in 1% 
PBS–paraformaldehyde. At least 700,000 cells were acquired on a 
BD FACS Canto II flow cytometer and then analyzed with FlowJo. 
Figures S3A,B in Supplementary Material shows the representa-
tive ICS gate strategies.
Purification of liver and heart 
lymphocytes
The perfused liver was lysed with collagenase buffer composed 
of 0.2  mg/mL collagenase IV (SIGMA), 0.02  mg/mL DNase 
(SIGMA), and 5% FBS. The leukocytes were separated on a 35% 
Percoll gradient (GE Healthcare), followed by centrifugation at 
600 × g for 20 min and at 4°C. The pellet was suspended in RPMI 
1640 (SIGMA) with 10% FBS (30). For the purification of the 
lymphocytes of the heart, we followed the protocol of Gutierrez 
et al. (31). Briefly, hearts collected from five mice at day 20 d.p.i. 
were minced, pooled, and incubated for 1 h at 37°C with RPMI 
1640, supplemented with NaHCO3, penicillin–streptomycin gen-
tamicin, and 0.05 g/mL of liberase blendzyme CI (Roche, Basel, 
Switzerland). The organs were processed in a Medimachine (BD 
Biosciences) in PBS containing 0.01% BSA. After tissue digestion 
and washes, cell viability was assessed by trypan blue exclusion, 
counted in a hemocytometer.
Flow cytometry analysis
Splenocytes were treated with ACK buffer for red cell lysis and 
washed with RPMI with 10% FBS. The spleen, heart, lymph node, 
and liver cells were stained with H2Kk-TEWETGQI multimer for 
10 min at RT. The cell surface was stained for 30 min at 4°C. The 
following antibodies were used for surface staining: anti-CD3 
APCcy7 (clone 145-2C11, BD), anti-CD8 PERCP or anti-CD8 
PACIFIC BLUE (clone 53-6.7, BD), anti-CD11a FITC (clone 
2D7, BD), anti-CD11c APCcy7 (clone HL3, BD), anti-CD44 
FITC (clone IM7, BD), anti-CD62L PE (clone MEL-14, BD), anti-
CXCR3 PERCP/Cy5.5 (clone 173, BioLegend), anti-CD27 FITC 
(clone LG3A10, BD), anti-CD4 PEcy7 (clone RM4-5, BD), anti-
KLRG1 FITC (clone 2F1, eBioscience), anti-CD49d PEcy7 (clone 
R1-2, BD), anti-CD69 PERCP (clone H1.2F3, BD), anti-CD43 
PEcy7 (1B11, BioLegend), anti-CD95 PEcy7 (clone JO2, BD), 
anti-CD25 FITC (clone LG3A10, BD), anti-CD127 PE (clone 
SB/199, BD), anti-CD122 FITC (clone TM-β1, BD), anti-CD38 
PE (clone 90, BD), anti-β7 PERCP (clone FIB27, BioLegend), 
anti-CD31 FITC (clone MEC 13.3, BD), anti-CD272 PE (clone 
8F4, eBioscience), anti-PD-1 FITC (clone J43, eBioscience), anti-
CTLA-4 PE (clone UC10-4B9, eBioscience), and anti-CCR7 PE 
(clone 4B12, BD). At least 500,000 cells were acquired on a BD 
FACS Canto II flow cytometer and analyzed with FlowJo 8.7.
In Vivo Proliferation assay
A/Sn were immunized with ASP-2 using the heterologous 
“prime-boost” vaccination regimen and infected with 150 
trypomastigotes forms of T. cruzi. At the moment of infection, 
mice were treated with monoclonal antibodies (LFA-1 or 2A3 
isotype control) and 2 mg of BrdU (5-bromo-2′-deoxyuridine, 
SIGMA) by route i.p., at every 48 h, until the 20th day after chal-
lenge. Then, 2 × 106 splenocytes were treated with ACK buffer 
for red cell lysis, washed with RPMI plus 10% FBS, and stained 
with H2Kk-TEWETGQI multimer and anti-CD8 antibody. The 
specific CD8+ T  cells were stained according BrdU-FITC Kit 
protocol (BD Pharmingen) for analysis of BrdU incorporation. 
A minimum of 700,000 cells were acquired on a BD FACS Canto 
II flow cytometer and analyzed with FlowJo 8.7.
In Vivo cytotoxicity assay
For the in vivo cytotoxicity assays, splenocytes collected from 
naive A/Sn mice were treated with ACK buffer to lyse the 
red blood cells, as described by Silverio et  al. (23). The cells 
were divided into two populations and were labeled with the 
fluorogenic dye carboxyfluorescein diacetate succinimidyl 
diester (CFSE; Molecular Probes, Eugene, OR, USA) at a final 
concentration of 10 µM (CFSEhigh) or 1 µM (CFSElow). CFSEhigh 
cells were coated with 2.5  µM of the TEWETGQI ASP-2 
peptide for 40 min at 37°C. CFSElow cells remained uncoated. 
Subsequently, CFSEhigh cells were washed and mixed with equal 
numbers of CFSElow cells before intravenous injection (2 × 107 
cells per mouse) into T. cruzi-infected, immunized and/or 
treated mice with anti-LFA-1 A/Sn recipients that were sedated 
with diazepam (20 mg/kg). Spleen cells from the recipient mice 
were collected at 20 h after adoptive cell transfer and fixed with 
1.0% paraformaldehyde. At least 100,000 cells were acquired on 
a BD FACS Canto II flow cytometer and analyzed with FlowJo 
8.7. The percentage of specific lysis was determined using the 
following formula:
 
%
%
%
 lysis
CFSE infected/%CFSE infected
CFSE nai
high low
high
= −
( )
1
ve/%CFSE naivelow( )×100
.
 
histology and immunohistochemistry
The mice’s heart, spleen, and liver were fixed in 10% formalin, and 
then dehydrated, embedded in paraffin blocks, and sectioned on 
a microtome. Staining was obtained with hematoxylin and eosin, 
and the number of amastigotes nests was quantified using a light 
microscope with 40× objective lens. Overall, 50 fields/group were 
counted. For immunohistochemistry the hearts of the animals 
were removed and frozen in Tissue-Tek O.C.T. (Sakura Finetek), 
and the 7 µm thickness cuts were made in the cryostat (Leica) and 
then fixed in ice-cold acetone for 15 min. The samples were stained 
with 20 µg of the biotinylated anti-CD8 antibody (clone 53-6.7, 
RD systems) for 12 h in the wet chamber, and after incubation 
was labeled with streptavidin Alexa Fluor® 488 (Thermo Fischer) 
at the concentration of 0.5  mg/mL, diluted 1:100 for 1  h and 
room temperature. The DAPI (4′,6-diamidino-2-phenylindole, 
SIGMA) dye was used for labeling the 5  mg/mL cell nucleus, 
diluted 1:1,000 for 15 min at room temperature. The images were 
acquired in the Confocal Leica TCS SP8 CARS microscope of 
the Institute of Pharmacology and Molecular Biology (INFAR) 
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of the Paulista School of Medicine of the Federal University of 
São Paulo. The images were obtained using the 63× objective and 
processed by the ImageJ program.
statistical analysis
The number of parasites/mL corresponding to the peak of para-
sitemia, the number of IFN-γ-producing cells (ELISPOT), and 
the absolute number of CD8+ T cells were compared by analysis 
of unidirectional variance (ANOVA); subsequently, the Tukey’s 
HSD test was used. To compare the survival of mice after challenge 
with T. cruzi, we used the Log-rank test. The receptor expression 
was compared using MFI (mean fluorescence intensity), and the 
naive group MFI was taken as the baseline. MFI was determined 
by the FlowJo software. Differences were considered significant 
when P value was <0.05.
resUlTs
lFa-1 is essential for survival of a/sn 
Mice during the experimental challenge 
with T. cruzi
Previously, we demonstrated that treatment with FTY720, 
which retains CD8+ T  cells in the lymph nodes via blockade 
of receptor S1Pr1, culminates in death of immunized mice. As 
LFA-1 and VLA-4 integrins were expressed on those specific 
CD8+ T cells we investigated the role of these molecules follow-
ing immunization and T. cruzi infection. To this end, immu-
nized and infected mice were treated with 250 µg of monoclonal 
antibodies anti-LFA-1 and/or anti-VLA-4 every 48 h to block 
those molecules. Initially, we analyzed blood parasitemia and, 
as shown in Figure 1A, mice treated with anti-LFA-1 (green) 
antibody had increased blood parasitemia when compared with 
the group only immunized and treated with the control isotype 
(red), whereas mice treated with anti-VLA-4 (yellow) had a 
parasite burden similar to the immunized (red). To examine 
whether these two integrins exhibit synergism, one group was 
treated with both antibodies simultaneously (Figure 1A, blue 
group). Simultaneous treatment resulted in increased blood 
parasitemia, but this increase was not significant when com-
pared with the group treated with anti-LFA-1 only, indicating 
that LFA-1, but not VLA-4, is important to control blood para-
sites. With respect to survival (Figure 1B), all mice treated with 
anti-LFA-1 died after 26 days, whereas all anti-VLA-4-treated 
mice and isotype control treated mice survived. Therefore, no 
statistical differences were observed in the survival rate between 
the mice treated with anti-LFA-1 (green) and the mice treated 
with both antibodies (blue), but there were differences in sur-
vival rate between the mice treated with anti-LFA-1 and mice 
treated with isotype control. Therefore, during LFA-1 blockade, 
mice displayed increased blood parasitemia and succumbed 
after challenge with T. cruzi, while VLA-4 blockade does not 
interfere with parasitemia and survival of treated mice.
To confirm the role of LFA-1 during T. cruzi infection, C57BL/6 
mice naturally resistant to T. cruzi infection were infected and 
treated. C57BL/6 mice treatment with anti-LFA-1 was able to 
control blood parasitemia until 12th day after infection, but after 
that, the blood parasitemia increased and all mice treated with 
anti-LFA-1 rapidly succumbed to infection (Figures 1C,D) when 
compare the mice treated with the isotype control.
Since LFA-1 blockade increased mouse susceptibility to 
infection by T. cruzi, we investigated the importance of the 
ICAM-1 integrin, a major ligand of LFA-1. To this end, 
genetically ICAM-1-deficient mouse was used. These mice were 
immunized and infected for parasitemia and survival analysis. 
Both C57BL/6 and ICAM-1 knockout mice displayed similar 
parasitemia, and the two groups immunized with the ASP-2 gene 
showed a decreased parasitemia when compared with the vector 
control immunized groups (Figure  1E). In addition, all mice 
survived the experimental challenge with T. cruzi (Figure 1F). 
Figure 1G shows the expression of CD54 (ICAM-1) on spleen 
of CD8+ T  cells of WT and deficient mice, and, as expected, 
the latter ones have lower expression of CD54 compared with 
WT mice. Altogether, these results indicate that the absence of 
ICAM-1 does not increase susceptibility to T. cruzi infection 
and suggest that, even though ICAM-1 is a major ligand of LFA-
1, there is another ligand (i.e., ICAM-2) that binds to LFA-1 
allowing it to exert its functions.
lFa-1 Blockade increases Tissue Parasite 
of immunized and infected a/sn Mice
Since anti-VLA-4 treatment did not interfere in the mice parasitemia 
and/or survival, all following experiments were performed by 
blocking LFA-1 integrin only. As the LFA-1 blockade leads to 
increased blood parasitemia and rapid death of the mice, we 
investigated whether the parasitic increase also occurs in the 
tissues of infected, immunized, and/or anti-LFA-1-treated A/Sn 
mice. The heart, liver, and spleen of these mice were extracted 
after the 20th day of infection for quantification of the parasite’s 
DNA by real-time PCR; in addition, the number of amastigote 
nests in the heart was quantified using hematoxylin–eosin stain-
ing. There was a statistical increase in the number of amastigote 
nests in the hearts of the LFA-1-treated mice compared with the 
immunized and infected group, and the largest amount of nests 
was found in the hearts of mice solely infected (Figures 2A,B). 
In addition, LFA-1 blockade resulted in the increase of parasites 
in the tissues analyzed compared with immunized, infected mice. 
The spleen showed higher parasite increase, followed by hearts 
and livers respectively (Figure  2C). These results demonstrate 
that treatment with anti-LFA-1 increases blood parasitemia, 
which will reflect on increased tissue parasite burden.
lFa-1 Blockade increases the expression 
level of the Fas/cD95 Molecule on the 
surface of effector cD8+ T cells
We analyzed whether LFA-1 blockade affects effector phenotype 
and activation of specific CD8+ T cells. To this end, splenocytes 
were stained with anti-CD8 and H2KK TEWETQGI-multimer, 
and surface markers. In previous results obtained by our group, we 
demonstrated that immunization followed by infection induces 
specific CD8+ T cells with the phenotype of effector cells (TE), 
which is characterized by the expression of CD11ahigh, CD44high, 
CD62Llow, and CD127low (25, 26). Anti-LFA-1 treatment increased 
FigUre 1 | LFA-1 blockade increases blood parasitemia and culminates in the death of A/Sn and C57BL/6 mice. A/Sn-, C57BL/6-, and intercellular adhesion 
molecule (ICAM)-deficient mice were immunized with plasmids pcDNA3 and/or pIgSPclone9 and adenoviral vectors Adβgal and AdASP-2. Fifteen days after the last 
immunization dose, mice were infected with 150 (A/Sn) and/or 104 (C57BL/6 and ICAM mice) blood trypomastigotes of the Y strain of Trypanosoma cruzi. 
Anti-VLA-4 and/or LFA-1 treatment was performed every 48 h after infection until the 20th days after infection. (a) Blood parasitemia was assessed, and values 
were log transformed and parasitemia data for each mice group are represented as mean ± SD for each group (n = 4). Values from peak parasitemia (day 12) were 
compared by one-way ANOVA and Tukey’s HSD tests, and the results were as follows: Significant differences were found between the red in green groups 
(P < 0.05). There were no significant differences between the blue group and the green group (P > 0.05). (B) Kaplan–Meier curves for survival of the different groups 
were compared using the log-rank test. The results of the comparisons were as follows: The mice in red group survived longer than the mice in green group. The 
survival rate of mice in the blue group was similar to the mice in the green group. (c) Log parasitemia data for each mice group (C57BL/6 mice infected and/or 
treated with anti-LFA-1) are represented as mean ± SD for each group (n = 4). Values from peak parasitemia (day 9) were no significantly different across the groups 
(P > 0.05). On day 14, significant difference was found between the infected and treated with anti-LFA-1 mice and infected and treated with the anti-2A3 isotype 
control mice (P < 0.05). (D) Kaplan–Meier curves for survival of the different groups were compared using the log-rank test. The results of the comparisons were as 
follows: the mice in yellow group survived longer than the mice in blue group. (e) Log parasitemia data for each mice group (ICAM-deficient and C57BL/6 mice) are 
represented as mean ± SD for each group (n = 4). Peak parasitemia values (day 9) were significantly different across C57BL/6 groups and in ICAM-deficient mice 
groups (P > 0.05). (F) Kaplan–Meier curves for survival of the different groups were compared, and there were no differences across groups. (g) MFI of CD54 
(ICAM-1) on CD8+ T cells from C57BL/6 and ICAM-deficient mice: the red line indicates MFI of naïve C57BL/6 mice, whereas the blue line indicates MFI of naïve 
ICAM-deficient mice. One out of two individual experiments is shown.
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the frequency and the absolute number of specific CD8+ T cells 
in the spleen (Figures 3A,B). In addition, as there is competi-
tion between the antibodies used for in vivo blockade and flow 
cytometric labeling, we observed a decrease in CD11a MFI in 
the anti-LFA-1-treated groups (Figure 3C). In general, the mark-
ers whose expression levels increased in the anti-LFA-1-treated 
group (Gr.3) in comparison with the infected group (Gr.1) or 
the immunized and infected group (Gr.2) were as follows: CD27, 
CD43, CD69, and CD95 (Figure 3C). Our group has also dem-
onstrated that the cells generated by immunization followed by 
infection expressed lower levels of CD95 on the surface compared 
with infected only group, and these cells were also resistant to 
death induced by anti-CD95 (12). Moreover, markers CD183, 
CD38, and PD-1 also displayed increased expression levels on the 
FigUre 2 | Treatment with anti-LFA-1 increases tissue parasitemia. A/Sn mice were immunized with ASP-2 using the heterologous “prime-boost” vaccination 
regimen, infected with 150 trypomastigotes forms of Trypanosoma cruzi and treated with anti-LFA-1 or isotype control until the 20th after infection. In this day, 
spleens, hearts, and livers of this mice were taken for quantification of the parasite DNA and count of amastigote nests in the heart. (a) Histological section of the 
heart; the arrows indicate the amastigote nests in each group. (B) Quantification of heart amastigote nests performed from 50 fields/group. (c) Quantification of the 
parasite DNA by real-time PCR in the different groups (Log) obtained from 50 ng of tissue DNA. Results represent mean ± SD for each group (n = 4) and to a single 
experiment. Asterisks represent statistical differences among the groups. Statistical analysis was performed using one-way ANOVA (*P < 0.001, **P = 0.000331, 
***P = 0.006602, and ****P < 0.01).
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surface of specific CD8+ T cells after treatment with anti-LFA-1 
(Gr.3) compared with Gr.2 (Figure 3C). KLRG1, however, had 
similar MFI among the three groups, and these groups showed 
low expression of markers CD122, BTLA, CTLA-4, and CD25. 
These results suggest that anti-LFA-1 treatment does not impair 
specific CD8+ T  cells in the spleen. Instead, there is a greater 
frequency and absolute number of these cells. In addition, the 
treatment did not alter the phenotype of effector CD8+ T cells 
(TE); however, we found in the spleen of treated mice that those 
CD8+ T cells expressed high levels of CD95.
specific cD8+ T cells accumulate  
in secondary lymphoid Organs  
and Decrease Migration into the  
heart after lFa-1 Blockade
After demonstrating that anti-LFA-1 treatment increases blood 
and tissue parasitemia and leads to mice death, our hypothesis 
was that specific CD8+ T cells cannot migrate into the infected 
tissues since LFA-1 is associated with leukocyte migration. To test 
our hypothesis, we measured in the spleen, lymph, blood, liver, 
and heart the frequency of specific CD8+ T cells. For that propose, 
the cells were labeled with anti-CD8 and H2KK-TEWETGQI 
multimer. We found higher frequency and increment in the 
absolute numbers of specific CD8+ T cells in spleens and lymph 
nodes, but not in the blood and liver of the anti-LFA-1-treated 
group when compared with the infected and immunized group 
(Figures  4A–F). A dramatic influx reduction of specific CD8+ 
T cells after anti-LFA-1 treatment (Figure 4A) was observed in 
group 3 hearts. In addition, we found that specific CD8+ T cells 
in the spleen, blood, and heart of the infected group (Gr.1) 
and the immunized and infected group (Gr.2) expressed high 
levels of CD11a, whereas the cells in the immunized, infected, 
and anti-LFA-1-treated group (Gr.3) showed decreased CD11a 
MFI due to the competition described earlier (Figure 4G). We 
also evaluated the frequency of total CD8+ T cells in the spleen, 
blood, and heart and, as shown in Figure S2 in Supplementary 
Material, there was a reduction in the frequency of CD8+ T cells 
in the heart of the anti-LFA-1-treated group (Figures S2A–D 
in Supplementary Material). Furthermore, by immunohisto-
chemistry, there is a decrease in the number of CD8+ T cells in 
the heart of animals treated with anti-LFA-1 (Figures S2E,F in 
Supplementary Material). The number of CD8+ T  cells in the 
heart of the treated group was similar to the infected group, and 
in relation to the immunized group, treatment with anti-LFA-1 
decreased the migration of CD8+ T cells to the heart, observed 
FigUre 3 | Effector CD8+ T lymphocytes express high levels of CD95 on the surface after anti-LFA-1 treatment. A/Sn mice were immunized with ASP-2 using the 
heterologous “prime-boost” vaccination regimen, infected with 150 trypomastigotes forms of Trypanosoma cruzi and treated with anti-LFA-1 or isotype control until 
the 20th after infection. In this day, the splenic cells were labeled with H2KK-TEWETGQI multimer, anti-CD8 and surface markers. (a) The frequency of specific CD8+ 
T cells in the spleen. (B) Absolute number of specific CD8+ T cells in the spleen. (c) Histograms with MFI of each marker analyzed in different groups. The red line 
represents the naive group, whereas the blue line represents groups 1, 2, and 3. Results in panels (a,B) are individual values with the mean ± SD of groups (n = 4), 
while in panel (c) representative analyses are shown for four mice per experiment. The experiment was performed two or more times with similar results. Statistical 
analysis was performed using the one-way ANOVA. Asterisks denote statistically significant differences between the groups 2 and 3 (P < 0.05).
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FigUre 4 | Continued
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FigUre 4 | Continued  
Specific CD8+ T cells accumulate in the spleen and lymph node and do not migrate into the heart after anti-LFA-1 treatment. A/Sn mice were immunized with ASP-2 
using the heterologous “prime-boost” vaccination regimen, infected with 150 trypomastigotes forms of Trypanosoma cruzi and treated with anti-LFA-1 or isotype 
control until the 20th after infection. In this day, spleen, heart, liver, lymph nodes, and blood cells of the immunized, infected, and treated or not with anti-LFA-1 were 
labeled with anti-CD8 and H2KK-TEWETGQI multimer. (a) Frequency of specific CD8+ T cells in the spleen, lymph node, blood, heart, and liver, respectively. (B–F) 
Absolute number of specific CD8+ T cells in the spleen, lymph node, blood, heart, and liver, respectively. The results for the spleen, lymph node, and liver are 
representative values of an individual in each group (n = 4) with mean ± SD. While the results for the blood and heart were taken from a pool of five individuals per 
group, values of an individual of each repetition (n = 2) with mean ± SD. Statistical analysis was performed using the one-way ANOVA. (g) Histograms represent 
MFI of specific CD8+ T cells that express CD11a onto the surface in the spleen, blood, and heart, respectively, and the group naïve the MFI of CD11a was analyzed 
onto the surface of CD8+ T cells. Asterisks denote statistically significant differences between of groups 2 and 3 (**P < 0.001).
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by the low number of these cells in the cardiac tissue. These 
results corroborate the decrease in specific CD8+ T cells in those 
organs. Therefore, during LFA-1 blockade, specific CD8+ T cells 
accumulate in the secondary lymphoid organs, such as spleen and 
lymph node, and cannot migrate into the heart, as observed by 
the lower frequency of these cells in that organ.
specific cD8+ T cells Degranulate and 
Produce iFn-γ and TnF-α after anti-lFa-1 
Treatment
Having in mind the important role of IFN-γ during infection by 
T. cruzi (2), we analyzed whether the anti-LFA-1 treatment may 
alter production of IFN-γ by specific CD8+ T cells. We also ana-
lyzed the effector function of specific CD8+ T cells in the spleen, 
liver, and lymph nodes regarding TNF-α production and indirect 
cytotoxicity involving cell surface mobilization of CD107a. 
The gate strategy used to evaluate the production of cytokines 
and the polyfunctionality of specific CD8+ T cells is illustrated 
in Figures S3A,B in Supplementary Material. In the spleen of 
the anti-LFA-1-treated group, compared with the immunized 
and infected group, there was an increase in the percentage of 
polyfunctional specific CD8+ T cells, that is, cells that are capable 
of degranulating and, at the same time, producing IFN-γ and 
TNF-α. Such increase in polyfunctionality of specific CD8+ 
T  cells after anti-LFA-1 treatment was also observed in lymph 
nodes and liver (Figures 5A,B). In addition, anti-LFA-1 treatment 
also culminated in an increase in the amplitude of the immune 
response, i.e., the percentage of specific CD8+ T cells producing 
IFN-γ or TNF-α or degranulating, in the spleen, lymph node, and 
liver (Figure 5C). The number of specific CD8+ T cells producing 
IFN-γ was higher in the anti-LFA-1-treated group (Gr.3), when 
compared with Gr.2, and this increase occurred in the spleen, 
the lymph node, and liver (Figure 5D). Altogether, these results 
show that LFA-1 blockade does not affect the effector function of 
specific CD8+ T cells regarding IFN-γ and TNF-α secretion and 
degranulation. The increase in the effector function is probably 
due to the accumulation of specific cells in spleen and lymph 
node after treatment with anti-LFA-1.
specific cD8+ T cells reduce Direct 
cytotoxicity against Target cells after 
Treatment with anti-lFa-1
First, we tested whether treatment had impaired the frequency 
and absolute numbers of specific CD8+ T cells. As we can see, there 
was an increase in the frequency and absolute numbers of specific 
CD8+ T  cells in the anti-LFA-1-treated group (Figures  6A,B). 
We concluded that the treatment did not interfere with specific 
CD8+ T cell expansion. Since specific CD8+ T cells are capable of 
secreting IFN-γ and TNF-α after LFA-1 blockade in the spleen, 
we assessed whether the treatment had impaired specific CD8+ 
T cells proliferative capacity. The proliferation of specific CD8+ 
T  cells in the spleen was analyzed in  vivo by thymidine BrdU 
analog incorporation. We found that a similar proportion of 
the H2KK-TEWETGQI CD8+ cells incorporated BrdU in  vivo 
in non-treated or treated mice indicating that the proliferative 
capacity of these cells was not significantly different (Gr. 2 and 
Gr. 3, Figure  6C). However, the infected mice have a greater 
proliferation in comparison with groups 2 and 3 (Figures 6C,D).
Another effector function triggered by specific CD8+ T cells is 
the direct cytotoxicity against the target cells. Here, we analyzed 
whether this function had been affected by the treatment. For that 
purpose, we used in vivo cytotoxicity assay. Figure 7A shows rep-
resentative histograms containing two populations P1 (CFSElow) 
and P2 (CFSEhigh) showing the specific lysis of H2KK-TEWETGQI 
peptide-labeled CFSEhigh cells from Gr.1, Gr.2, and Gr.3 groups 
(Figure 7A). Surprisingly, we observed that the immunized mice 
treated with anti-LFA-1 had significantly decreased cytotoxicity 
when compared with the immunized group (Figure  7B). The 
specific CD8+ T  cells from the immunized mice have 80% 
cytotoxicity whereas the anti-LFA-1-treated cells showed a 29% 
percentage drop. Figure 7C shows that the numbers of CFSElow 
cells were similar across groups 1, 2, and 3, while the number of 
cells CFSEhigh decreased in groups 2 (non-treated) and 3 (treated) 
compared with group 1 (Figure 7D).
The reduction of cytotoxicity did not affect the amount of 
granzyme B produced by specific CD8+ T cells in the anti-LFA-
1-treated group. We observed that MFI and the percentage of 
specific CD8+ T  cells that produce granzyme B were similar 
across the groups (Figures 7E,F). These results demonstrate that 
treatment with LFA-1 directly affects the cytotoxicity of specific 
CD8+ T cells and the impairment of this function may be one of 
the factors responsible for the reversal protection generated by 
immunization observed after LFA-1 blockade.
DiscUssiOn
Our group previously demonstrated that the recirculation of spe-
cific CD8+ T cells generated by heterologous prime-boost immu-
nization and T. cruzi infection is of paramount importance to the 
protection of A/Sn mice, which are highly susceptible to infection 
by T. cruzi (12, 13). Given that integrins play an important role 
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FigUre 5 | Continued
FigUre 6 | Specific CD8+ T cells can proliferate after the treatment with anti-LFA-1. A/Sn mice were immunized with ASP-2 using the heterologous “prime-boost” 
vaccination regimen, infected with 150 trypomastigotes forms of Trypanosoma cruzi, and treated with anti-LFA-1 or isotype control until 20th days after infection. 
Mice received 2 mg of 5-bromo-2′-deoxyuridine (BrdU) every 48 h. In this day, spleen was harvested for the proliferation assay. 2 × 106 splenocytes were labeled 
with H2KK-TEWETGQI multimer, anti-CD8 and anti-BrdU. (a,B) The frequency and absolute number of specific CD8+ T cells in the spleen, respectively. (c,D) 
Histograms with MFI of BrdU in the groups and graph of the MFI mean of the specific CD8 T cells expressing BrdU. The graphs represent the mean ± SD for each 
individual (n = 3). Representative results of two independent experiments. Statistical analysis was performed using one-way ANOVA test (**P < 0.01; ***P < 0.005).
FigUre 5 | Continued  
Anti-LFA-1 treatment increases the polyfunctionality of specific CD8+ T cells in the spleen, liver, and lymph node, and the number of IFN-γ-producing cells. A/Sn 
mice were immunized with ASP-2 using the heterologous “prime-boost” vaccination regimen, infected with 150 trypomastigotes forms of Trypanosoma cruzi, and 
treated with anti-LFA-1 or isotype control until 20th days after infection. In this day, splenocytes and cells of inguinal lymph nodes were collected. Furthermore, 
leukocytes from the liver were isolated by Percoll. These cells were restimulated in vitro in the presence of the peptide TEWETGQI at a final concentration of 10 mM. 
After 12 h, cells were stained for CD8, IFN-γ, and TNF-α. Frequencies were initially estimated for any CD8+ that expressed surface CD107a, IFN-γ, or TNF-α after 
stimulation in vitro with peptide TEWETGQI. (a) Percentage of specific CD8+ T cells performing each of the functions shown in the graph combinations; (+) indicates 
presence, while (−) indicates absence of CD107a/IFN-γ/TNF-α. (B) Pie chart represents the fraction of specific CD8+ T cells that carry each of the combinations 
shown in the legend. (c) Amplitude of the immune response, i.e., the percentage of CD8+ T cells that are performing at least one of the functions indicated. (D) 
ELISPOT graph of the IFN-γ-producing cells. Results are representative of two independent experiments with the mean ± SD of each individual shown in the graphs 
(n = 4). Asterisks show statistical difference between the groups. Statistical analysis was performed using one-way ANOVA (P < 0.05). Boolean analysis was 
performed using FlowJo software. SFC, spot-forming cell.
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in cell–cell and cell–extracellular matrix interactions, and that 
these interactions are responsible for the intracellular signal 
transduction that culminates in cell migration (14) and formation 
of the immunological synapse (15), the aim of this study was to 
analyze the role of LFA-1 and VLA-4 integrins in specific CD8+ 
T  cells migration. During activation of specific CD8+ T  cells, 
there was an increase in the expression level of CD11a (LFA-1) 
and CD49d (VLA-4) chains (12). In addition, an increase in 
effector CD8+ T cells that express molecules LFA-1/ICAM-1 and 
VLA-4/VCAM-1 occurred in the hearts of mice infected with T. 
cruzi, suggesting the role of these molecules in the migration of 
specific CD8+ T cells into infected tissues (22, 23, 32). Here, we 
investigated the hypothesis that these molecules participate in the 
migration of specific CD8+ T  cells generated by immunization 
and infection. LFA-1 blockade, but not VLA-4, makes vaccinated 
A/Sn and infected C57BL/6 mice susceptible to infection with T. 
cruzi. The increased susceptibility of A/Sn mice was accompanied 
by increased parasitemia and tissue parasite burden, as well as 
rapid death of these mice. Even though VLA-4 does not play any 
role in our model, it participates in the migration of specific CTLs 
into the heart of C3H/He mice when infected with the Colombian 
strain of T. cruzi (22). Because we did not see any role of VLA-4 
in the mice parasitemia and survival our study was conducted 
toward LFA-1 role.
To analyze the role of ICAM-1, a major ligand for LFA-1, 
we used ICAM-1 KO mice and challenged them with blood 
FigUre 7 | Anti-LFA-1 treatment affects the in vivo cytotoxicity of specific CD8+ T cells. A/Sn mice were immunized with ASP-2 using the heterologous “prime-
boost” vaccination regimen, infected with 150 trypomastigotes forms of Trypanosoma cruzi, and treated with anti-LFA-1 or isotype control until 20th days after 
infection. After that, the spleen was harvested for the cytotoxicity assay. Splenocytes from naive mice were used for labeling with CFSElow (1 µM) and CFSEhigh 
(10 µM); the CFSEhigh population was pulsed with the 2.5 µM of peptide TEWETGQI. The mice immunized and anti-LFA-1 treated or untreated received 10 × 106 
cells from each population via retro-orbital route. In addition, for analysis of granzyme B expression by the specific CD8+ T cells, 2 × 106 splenocytes were 
stimulated in vitro with 10 µM TEWETGQI peptide. After 12 h, the splenocytes were collected for intracellular labeling of granzyme B. (a) The histograms represent 
the evens of CFSElow (P1) and CFSEhigh (P2) cells in each group. (B) Percentage of the cytotoxicity of specific CD8+ lymphocytes with the mean ± SD for each 
individual (n = 6). (c,D) The graphs with the mean cells CFSElow and CFSEhigh in the spleen of mice. (e,F) Histograms and the graph represent MFI and the 
percentage of specific CD8+ T cells that express granzyme B, respectively. The graphs represent the mean ± SD for each individual (n = 3). Representative results of 
two independent experiments. Statistical analysis was performed using one-way ANOVA test (***P < 0.01; ****P = 0.0047).
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trypomastigotes of the Y strain of T. cruzi, which did not affect 
the susceptibility of these mice to infection. This may be related 
to the redundancy of ligands by which a receptor can connect to 
alternate ligands without complete loss of functions performed 
by a receptor (33–35).
LFA-1 acts as a co-stimulatory molecule participating in the 
activation of T  lymphocytes (36), and it has been shown that 
this molecule activates CD4+ T  cells and induces secretion of 
cytokines such as IFN-γ and IL-17 (37). Therefore, we evaluated 
whether LFA-1 blockade impairs the activation of specific CD8+ 
T cells or interferes with phenotype of effector CD8+ T cells (TE). 
Our group has characterized the profile of CD8+ T cells induced 
by immunization that displays a phenotype of effector CD8+ 
T cells (TE). TE cells are characterized by expression of CD44high, 
CD62Llow, and CD127low (26), and we evaluated this profile and 
other activation markers on the cells from anti-LFA-1-treated 
mice. The anti-LFA-1 blockade decreased the CD11a MFI on 
specific CD8+ T cells surface by approximately 50%. In addition, 
treatment did not affect the phenotype of effector CD8+ T cells as 
well as the expression of early and late activation markers, such 
as CD69 and CD44, respectively. Results obtained by Gérard and 
colleagues also showed that the absence of LFA-1 does not reduce 
the expression of CD69 on CD8+ T cells (38).
The lower expression of CD95 in the cells induced upon vac-
cination was the main difference to CD8+ T cells generated by 
the infection, which had higher levels of CD95 (25). There is an 
increase in the expression of Fas/CD95 on some specific CD8+ 
T cells after immunization and treatment with anti-LFA-1. This 
result suggests that specific CD8+ T  cells in mice treated with 
anti-LFA-1 may be more susceptible to programmed cell death by 
the extrinsic pathway. Similar results were shown by Borthwick 
and colleagues, who found that LFA-1 blockade reduces the 
survival of T lymphocytes, thus suggesting the important role of 
LFA-1 in survival signals during the process of T cells migration 
(39). Otherwise, reduction of migration to tissues upon LFA-1 
blockade might increase effector CD8 T-cells expressing Fas in 
the secondary lymphoid organs.
Indeed, there is an impaired migration of specific CD8+ 
T  cells after LFA-1 blockade. The number of these cells was 
quantified in the spleen, heart, liver, lymph nodes, and blood 
after anti-LFA-1 treatment. The treatment led to an increase in 
the frequency and absolute number of specific CD8+ T cells in 
the spleen and lymph node, and a decreased frequency mainly 
in the heart. However, despite the apparent decrease in the 
overall number of CD8 T cells in blood, this decrease was not 
statistically significant (Figure S2 in Supplementary Material). 
We have previous described that specific-peptide CD8+ activa-
tion occurs in the lymph nodes after subcutaneous infection by T. 
cruzi and also in vaccinated model (12, 13). We approached this 
subject by administering the immunosuppressive drug FTY720 
(12, 13). In both models, this drug reduced lymphocyte recir-
culation by interfering with T  cell signaling via S1Pr1. This 
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interference resulted in inhibition of S1Pr1 signaling, effectively 
trapping T  cells within the lymph node without inhibiting 
T cell activation. FTY720 administration significantly impaired 
protective immunity supporting the hypothesis that T  cell 
recirculation is critical for the protective immunity they mediate 
(12, 13). Here, we have not addressed how these cells accumulate 
more in the lymph after treatment with anti-LFA-1. However, our 
data confirm that recirculation of these cells is necessary to exert 
their effector function in the peripheral tissues. Thus, blocking 
the integrin LFA-1, we observed the same accumulation not only 
in the lymph node but also in the spleen. However, in our immu-
nization, infection, and treatment model, there was no change 
in the number of specific CD8+ T cells in the peripheral blood 
(Figure S2 in Supplementary Material), probably because of the 
increased accumulation of CD8+ T cells in the spleen and lymph 
node. This phenomenon may be specific to our immunization 
and infection model but has not yet been explored in details 
or found in another model. One explanation might be that the 
blockage of LFA-1 integrin expressed by CD8+ T cells prevents 
the interactions with its ligand might be required to exit from 
lymph node. Another explanation might be due the decreased 
speed or movement of these cells (40). These issues need to 
be further addressed in our vaccination and infection model. 
These results confirm that LFA-1 is important to the migration 
of specific CD8+ T cells into infected tissues such as the heart, 
and the decline of these cells should be one of the causes for 
increased parasitemia in that organ. Recent studies have shown 
that LFA-1 blockade, and not VLA-4, reduces migration speed of 
T lymphocytes, leading to decreased antigen scanning by T cells 
(41) and, hence, lower immune response and higher parasitemia.
We also evaluated whether anti-LFA-1 treatment would affect 
the effector function of specific CD8+ T  cells, since these cells 
accumulated in the spleen are incapable of controlling the number 
of parasites. We analyzed the production of pro-inflammatory 
cytokines, crucial for controlling T. cruzi multiplication, such as 
IFN-γ and TNF-α, and observed that there was accumulation of 
polyfunctional specific CD8+ T cells capable of degranulating and 
simultaneously producing TNF-α and IFN-γ in the spleen, lymph 
node and liver. As the LFA-1 blockade retained CD8+ T  cells in 
the spleen and lymph node, we believe that this accumulation led 
to increased effector function of these cells. In the liver, in which 
there was no accumulation of such cells, the increase in intracel-
lular cytokine production can be explained by the fact that LFA-1 
blockade does not affect the production of those cytokines. 
In addition, it has been shown that high doses of anti-LFA-1 were 
required for impairing the production of those mediators (42). 
Finally, specific CD8+ T cells proliferated after LFA-1 blockade, and 
this result was consistent with the data obtained by Gérard et al. (38).
Another important function triggered by specific CD8+ 
T cells is the direct cytotoxicity against target cells. NK cyto-
toxic cells and CTLs of chagasic patients express perforin and 
granzyme B, suggesting the importance of these mediators to 
the host immune response (43). In addition, specific CD8+ 
T cells induced by immunization are cytotoxic and can produce 
perforin (2). Anti-LFA-1 treatment decreased the 80% cytotox-
icity of specific CD8+ T cells in the immunized group to 60% 
after treatment. Similar results were obtained by Petit et  al., 
whereas LFA-1 blockade was responsible for a 50% decrease of 
direct cytotoxicity triggered by CD8+ T cells (42). In addition, 
the decrease in cytotoxicity is independent of cytotoxic granule 
production and degranulation because there was no decrease 
in the amount of granzyme B and CD107a in specific CD8+ 
T  cells treated with anti-LFA-1. We believe that cytotoxicity 
is impaired not because of the reduction of cytotoxic granules 
but because LFA-1 is important to maintain stability between 
target and cytotoxic cells. The role of LFA-1 in maintaining a 
stable contact between the cells was demonstrated by blocking 
β2 chain of LFA-1, since absence of such molecule impaired the 
formation time of cell protrusions, as well as the stability of the 
immunological synapse (44–47). Also, it has been shown that 
LFA-1 blockade impairs close contact between effector T cells 
and antigen-presenting cells (48).
The reduction of direct cytotoxicity may explain why specific 
CD8+ T cells cannot control the number of parasites in the spleen 
even if accumulation of these cells occurs during LFA-1 blockade. 
In addition, our results suggest that LFA-1 plays an important 
role in the migration of specific CD8+ T cells into the heart and 
the survival of these cells. Finally, we believe that impairment of 
direct cytotoxicity and lower migration of specific CD8+ T cells 
into the heart are the major causes of lack of protection to T. cruzi 
infection upon immunization and treatment with anti-LFA-1.
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